The global basal cell carcinoma treatment market size was estimated to be USD 7.36 billion in 2023 and is expected to reach at USD 17.38 billion by 2034 with a CAGR of 8.12% during the forecast period 2024-2034. The increasing occurrence of basal cell carcinoma, advancements in treatment methodologies, heightened awareness among individuals regarding early disease detection, a rise in the prevalence of skin malignancies, a growing elderly population, and increased research & development efforts in the treatment of basal cell carcinoma are some of the key factors boosting the market growth.
Basal cell carcinoma, the most prevalent form of non-melanoma skin cancer, is commonly known as 'rodent ulcers.' The skin's top layer, the epidermis, contains three primary cell types, with basal cells lining these layers. The basal cells undergo shedding or replacement as new ones develop. This carcinoma manifests as open sores, red patches, shiny bumps, or slightly raised growth on the skin with rolled edges. While basal cell carcinoma is generally painless and non-metastatic, there are rare instances where it may spread to other parts of the body. Therefore, increased research & development efforts in the treatment of basal cell carcinoma is predicted to boost the market growth during the forecast period. For instance, in December 2023, AiViva Biopharma reported encouraging results from the phase 1/2 clinical trial of AIV001 (Axitinib), a new intradermal treatment, for patients diagnosed with basal cell carcinoma (BCC).
By treatment, surgery was the highest revenue-grossing segment in the global basal cell carcinoma treatment market in 2023 owing to the increasing advancements in surgical techniques, growing demand for minimally invasive procedures, a heightened awareness of skin cancer, and growing demand for early diagnosis and treatment. Additionally, medications is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in personalized medicine are on the rise, coupled with an increasing awareness of early detection and a surge in regulatory approvals. For instance, in November 2022, According to Regeneron Pharmaceuticals, Inc., Libtayo is now approved by the European Commission (EC) to be used in the treatment of certain patients with advanced basal cell carcinoma (BCC).
By end-user, hospital was the highest revenue-grossing segment in the global basal cell carcinoma treatment market in 2023 owing to the increasing investments are being made to adopt advanced medical devices. Hospitals serve as crucial centers for managing patients, fostering collaboration among healthcare professionals, and advancing research and development. The collaborative endeavors within hospitals are expected to improve cancer care, with a particular emphasis on enhancing patient outcomes, early detection, and tailoring treatment plans based on individual needs. For instance, in September 2022, Royal Hampshire County Hospitals have obtained the FotoFinder equipment to enhance their capabilities in caring for skin cancer. The FotoFinder mole mapping device will significantly transform the dermatology team's ability to identify, monitor, and address skin cancer in patients from the region. Additionally, specialty clinics is predicted to grow at the fastest CAGR during the forecast period owing to the escalating healthcare spending, increasing incidence of basal cell carcinoma, and a growing need for innovative treatment alternatives.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing occurrence of melanoma cancer, a rising elderly population, heightened research and development initiatives by major market participants, a surge in favorable reimbursement conditions, and an increase in the number of clinical trial processes. For instance, in January 2023, Sirnaomics Ltd. has declared its progression in the clinical development of STP705 to address two non-melanoma skin cancers: Squamous Cell Carcinoma in situ (isSCC) and Basal Cell Carcinoma (BCC). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising occurrence of skin diseases, an increase in awareness about advanced treatments, a growing prevalence of basal cell carcinoma, and heightened collaborations among prominent market players. For instance, in October 2023, Sun Pharma announced that its collaborative partner, the Swiss-Italian biotech company Philogen, has disclosed favorable outcomes from late-stage clinical trials for its novel drug Nidlegy (daromun), designed for the treatment of skin cancers.
Basal cell carcinoma, the most prevalent form of non-melanoma skin cancer, is commonly known as 'rodent ulcers.' The skin's top layer, the epidermis, contains three primary cell types, with basal cells lining these layers. The basal cells undergo shedding or replacement as new ones develop. This carcinoma manifests as open sores, red patches, shiny bumps, or slightly raised growth on the skin with rolled edges. While basal cell carcinoma is generally painless and non-metastatic, there are rare instances where it may spread to other parts of the body. Therefore, increased research & development efforts in the treatment of basal cell carcinoma is predicted to boost the market growth during the forecast period. For instance, in December 2023, AiViva Biopharma reported encouraging results from the phase 1/2 clinical trial of AIV001 (Axitinib), a new intradermal treatment, for patients diagnosed with basal cell carcinoma (BCC).
By treatment, surgery was the highest revenue-grossing segment in the global basal cell carcinoma treatment market in 2023 owing to the increasing advancements in surgical techniques, growing demand for minimally invasive procedures, a heightened awareness of skin cancer, and growing demand for early diagnosis and treatment. Additionally, medications is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in personalized medicine are on the rise, coupled with an increasing awareness of early detection and a surge in regulatory approvals. For instance, in November 2022, According to Regeneron Pharmaceuticals, Inc., Libtayo is now approved by the European Commission (EC) to be used in the treatment of certain patients with advanced basal cell carcinoma (BCC).
By end-user, hospital was the highest revenue-grossing segment in the global basal cell carcinoma treatment market in 2023 owing to the increasing investments are being made to adopt advanced medical devices. Hospitals serve as crucial centers for managing patients, fostering collaboration among healthcare professionals, and advancing research and development. The collaborative endeavors within hospitals are expected to improve cancer care, with a particular emphasis on enhancing patient outcomes, early detection, and tailoring treatment plans based on individual needs. For instance, in September 2022, Royal Hampshire County Hospitals have obtained the FotoFinder equipment to enhance their capabilities in caring for skin cancer. The FotoFinder mole mapping device will significantly transform the dermatology team's ability to identify, monitor, and address skin cancer in patients from the region. Additionally, specialty clinics is predicted to grow at the fastest CAGR during the forecast period owing to the escalating healthcare spending, increasing incidence of basal cell carcinoma, and a growing need for innovative treatment alternatives.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing occurrence of melanoma cancer, a rising elderly population, heightened research and development initiatives by major market participants, a surge in favorable reimbursement conditions, and an increase in the number of clinical trial processes. For instance, in January 2023, Sirnaomics Ltd. has declared its progression in the clinical development of STP705 to address two non-melanoma skin cancers: Squamous Cell Carcinoma in situ (isSCC) and Basal Cell Carcinoma (BCC). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising occurrence of skin diseases, an increase in awareness about advanced treatments, a growing prevalence of basal cell carcinoma, and heightened collaborations among prominent market players. For instance, in October 2023, Sun Pharma announced that its collaborative partner, the Swiss-Italian biotech company Philogen, has disclosed favorable outcomes from late-stage clinical trials for its novel drug Nidlegy (daromun), designed for the treatment of skin cancers.
Segmentation: Basal Cell Carcinoma Treatment Market Report 2023 - 2034
Basal Cell Carcinoma Treatment Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Medication
- Surgery
- Others
Basal Cell Carcinoma Treatment Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Specialty Clinics
- Hospitals
- Others
Basal Cell Carcinoma Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Basal Cell Carcinoma Treatment Market: Treatment Estimates & Trend Analysis
8. Basal Cell Carcinoma Treatment Market: End-user Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Basal Cell Carcinoma Treatment Market
11. Europe Global Basal Cell Carcinoma Treatment Market
12. Asia Pacific Global Basal Cell Carcinoma Treatment Market
13. Latin America Global Basal Cell Carcinoma Treatment Market
14. MEA Global Basal Cell Carcinoma Treatment Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- NeonMind BioSciences
- Cybin Corp.
- Pfizer Inc.
- Usona Institute
- Numinus
- Jazz Pharmaceuticals
- Havn Life
- Revive Therapeutics
- Seelos Therapeutics
- PharmaTher Holdings Ltd
- NRx Pharmaceuticals Inc.
- Mind Medicine
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 7.36 Billion |
| Forecasted Market Value ( USD | $ 17.38 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
